Internal Medicine · San Francisco, CA
NPI
1174596969
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
45 Castro St, Suite 423
San Francisco, CA, 94114
Phone (415) 551-9758
Groups this clinician bills Medicare through
Medicare paid, 2024
$96K
1,221 services
Medicare patients, 2024
273
Average age 72
Drug cost, 2024
$5.4M
8,078 prescriptions
Company payments, 2025
$2,822
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Virginia I Cafaro was code 99214 (office e&m - established), 251 times for 143 patients. In total Virginia I Cafaro billed 1,221 services in 41 codes, and Medicare paid $96K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 251 | 143 | $108.11 | $27K |
| 99213 Office E&M - Established | Office | 188 | 136 | $72.70 | $14K |
| 99215 Office E&M - Established | Office | 97 | 70 | $148.24 | $14K |
| 91322 Vaccine Product | Office | 51 | 44 | $151.77 | $7,740 |
| G0008 Administration of influenza virus vaccine | Office | 50 | 50 | $38.68 | $1,934 |
| 90480 Vaccine Administration | Office | 46 | 40 | $51.59 | $2,373 |
| 90653 Vaccine Product | Office | 46 | 46 | $81.82 | $3,764 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 44 | 44 | $155.73 | $6,852 |
| 90677 Vaccine Product | Office | 23 | 23 | $290.08 | $6,672 |
| G0009 Administration of pneumococcal vaccine | Office | 23 | 23 | $38.68 | $890 |
| G0438 Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 17 | 17 | $196.02 | $3,332 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 16 | 15 | $14.79 | $237 |
| 93000 Electrocardiogram | Office | 15 | 15 | $12.97 | $195 |
| 96127 Behavioral Health Services | Office | 11 | 11 | $4.03 | $44.37 |
By year: 2022 $45K for 486 services; 2023 $55K for 624 services; 2024 $96K for 1,221 services.
Medicare prescription drug claims, 2024
In 2024, the drug Virginia I Cafaro prescribed most often to Medicare patients was Atorvastatin Calcium, with 316 prescriptions and refills. In total Virginia I Cafaro wrote 8,078 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 316 | 710 | 79 | $2,701 |
| Rosuvastatin Calcium Generic | 248 | 589 | 70 | $3,526 |
| Tivicay Dolutegravir Sodium | 239 | 282 | 30 | $674K |
| Amlodipine Besylate Generic | 226 | 478 | 55 | $1,153 |
| Dovato Dolutegravir Sodium/Lamivudine | 225 | 255 | 28 | $750K |
| Gabapentin Generic | 185 | 271 | 51 | $2,870 |
| Acyclovir Generic | 168 | 345 | 43 | $3,617 |
| Losartan Potassium Generic | 153 | 382 | 45 | $1,680 |
| Levothyroxine Sodium Generic | 140 | 341 | 41 | $1,886 |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 138 | 146 | 17 | $605K |
| Lisinopril Generic | 131 | 293 | 36 | $1,049 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 130 | 132 | 15 | $498K |
| Omeprazole Generic | 124 | 247 | 35 | $1,897 |
| Testosterone Generic | 124 | 138 | 28 | $14K |
| Pifeltro Doravirine | 119 | 152 | 19 | $279K |
Brand drugs: 2,177 claims; generic drugs: 5,871 claims; opioid claims: 215.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Virginia I Cafaro $2,822 ($2,822 in general payments such as food, travel and fees) from 23 companies. The largest payer was ViiV Healthcare Company with $559.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 34 | $559 |
| Gilead Sciences, Inc. GILD | 17 | $381 |
| Abbvie Inc. ABBV | 15 | $318 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $230 |
| Novo Nordisk Inc NVO | 7 | $177 |
| Merck Sharp & Dohme LLC MRK | 6 | $167 |
| Pfizer Inc. PFE | 5 | $142 |
| Theratechnologies Inc. THTX | 5 | $138 |
| Lilly USA, LLC LLY | 4 | $111 |
| Astellas Pharma US Inc 4503.T | 4 | $106 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.